Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression Abstract #1883

Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.
Aim(s): Assess the efficacy of NETest in BPNET diagnosis and identification of progressive disease.
Materials and methods: Material: BPNETs: (n=108), controls (n=90), COPD (n=18) and lung cancers (n=12). Measurements: NETest (+ve >14%) by qPCR; CgA by ELISA (normal <109ng/ml); disease status by imaging. Carcinoids were typical TC: n=64, atypical AC: n=44. Clinico-histological groups were AC/SD or AC/PD; TC/SD or TC/PD by RECIST. Progressive disease (PD): 43% AC and 23% TC. Analysis: 2-tailed Mann-Whitney U-tests and ROC-statistics.
Conference: 14th Annual ENETS conference (2017)
Category: Non digestive NETs (bronchial, MTC pheochromocytoma) Pathology, grading, staging
Presenting Author: Professor Mark Kidd
Keywords: NET

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1571 Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease
Introduction: Broncho-Pulmonary (BP) NETs are pulmonary neoplasms with indolent to aggressive behavior. Imaging, histology and biochemistry are limited in defining malignancy or progression
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: PCR
#2220 Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors
Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Professor Mark Kidd
#2282 Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with Appendiceal Neuroendocrine Neoplasms (ANEN) Based on Clinical Follow-up and Results of NETest
Introduction: Neuroendocrine neoplasms of the appendix (ANEN) are one of the most commonly identified gastroentropancreatic tumours (GEP). The aim of this retrospective study was to review the value of Somatostatin Receptor Scintigraphy (SRS) in staging and imaging follow-up of patients with confirmed ANEN, NENG1 and NENG2 in single institution.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Sonia Konsek
#1666 Prognosis and Incidence in Pancreatic and Gastrointestinal Neuroendocrine Neoplasms with Emphasis on “NET G3”: An Analysis of 198 Cases from Japan
Introduction: Prognostic impact of well differentiated pancreatic neuroendocrine neoplasms (PanNENs) with a Ki67 >20%, provisionally called NET G3, needs to be validated and compared to poorly differentiated neuroendocrine carcinomas (NECs). Moreover, the frequency of NET G3 among gastrointestinal NENs (GI-NENs) has so far not been studied.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Atsuko Kasajima
Keywords: NET G3, GEP-NEN, GI-NET
#1485 Validation of a Blood Neuroendocrine Tumor Gene Signature, the NETest, in a Netherlands NET Cohort
Introduction: The CgA has limitations as a monoanalyte biomarker. The introduction of a PCR-based multi-analyte analysis of 51 genes (NETest) has been proposed as more accurate.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Margot Tesselaar
Authors: Tesselaar M, Korse T, Kidd M, Verbeek W, ...